News

The company plans to combine the probes with its proprietary signal amplification technologies, which will enhance their effectiveness by allowing visualization at levels not achievable by other methods.

The outcome of this trial is anticipated to support a supplemental new drug application (sNDA), which the company hopes to file with the FDA in the second quarter

The preliminary recommendations from the National Institute for Health and Clinical Excellence (NICE), the body that provides guidance to the UK National Health Service, looked at the aromatase

The studies, named PROVE 1 and PROVE 2, will be conducted in the US and Europe as part of a global phase II development program for VX-950. Together,

Rylomine is a patient-controlled nasal spray that delivers a single, metered dose of morphine, an opioid analgesic used for the treatment of moderate-to-severe pain. After use, a negligible

According to Dov an unusually high placebo response rate was the single major contributory factor to the failure of the trial. The company also said that the severity

This is the first study to identify a potential treatment option for patients who suffer from this variation of irritable bowel syndrome (IBS). The findings were presented at

Results from the phase III trial, dubbed CHARM, showed that remission rates were maintained through 56 weeks in patients who demonstrated response to Humira during the initial four-week

The study is being conducted under the guidance of a special protocol assessment (SPA) provided by the FDA. The SPA indicates that if the trial successfully meets its